Search

i-FACTOR is a composite bone substitute material consisting of a P-15 synthetic collagen fragment adsorbed onto an organic bone mineral and suspended in an inert biocompatible hydrogel carrier. Previous analyses of the US FDA IDE study demonstrated the benefits of i-FACTOR compared to local autograft bone in single-level ACDF at 12- and 24-months postoperative. We report 6-year clinical and radiological outcomes of post-approval study. Subjects from a completed, prospective, randomized, controlled, multicenter clinical trial that was conducted at 22 North American sites were enrolled in a post-approval study and we report 6-year outcomes. Of 319 subjects that participated in the IDE study, 220 were enrolled into post-approval 6 years follow-up autograft (n = 114) or i-FACTOR (n = 105) in a cortical ring allograft. Radiological, clinical, and patient-reported outcomes. Subjects completed prospective, randomized, controlled, multicenter clinical trial that was conducted at 22 North American sites were enrolled into post-approval study 6 years follow-up. Fusion rates at 72 months were 99.0% in i-FACTOR subjects and 98.2% in autograft subjects, with a difference of 0.8% (95% C.I., (95% CI -2.3%, 4.0%). Mean improvement in NDI in i-FACTOR subjects was 28.56 (95% CI 24.79, 32.33) compared to 29.17 (95% CI 25.46, 32.88) in autograft subjects, with a difference of -0.61 (2.793) (95% CI -6.10, 4.88). Neurologic success rate at 72 months was 95.89% in i-FACTOR subjects and 93.33% in autograft subjects, with a difference of 2.6% (95% CI, -4.70%, 9.81%). Overall success rate was 68% in i-Factor and 62% in autograft subjects. Safety outcomes were similar between the 2 treatment groups. Secondary surgery at any cervical level occurred in 20 (18.9%) i-FACTOR subjects and 23 (20.2%) autograft subjects (p=0.866). Pain and SF-36 outcomes were similar between the groups at all study visits. There were no adverse reactions associated with i-FACTOR. At 6 years, i-FACTOR in ACDF resulted in similar outcomes compared to local autograft. Safety outcomes are acceptable and clinical and functional outcomes for i-FACTOR in the previous studies are confirmed. I-Factor (Approved for this indication) [ABSTRACT FROM AUTHOR]